Lynparza (olaparib) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
• member is in complete or partial response to first-line platinum-based chemotherapy (e.g., carboplatin, oxaliplatin)
• member has deleterious or suspected deleterious BRCA-mutated disease OR other criteria continue beyond visible text